Buy EB-002 (EB-373)

Buy EB-002 (EB-373)

EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders.^{[1][2][3][4][5]} It is taken orally.^[1] The drug is under development by Enveric Biosciences.^[1][2][3][5] As of November 2024, it is in the preclinical research stage of development.^[1][2] In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million.^[3] Its exact chemical structure does not yet appear to have been disclosed.^[1]